

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

INSIDE INFORMATION

**(1) DELAY IN PUBLICATION OF THE 2025 ANNUAL RESULTS;
(2) POSTPONEMENT OF BOARD MEETING;
AND (3) SUSPENSION OF TRADING OF THE SHARES**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of China Health Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2)(a) and 13.49(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

DELAY IN PUBLICATION OF THE 2025 ANNUAL RESULTS

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) that there will be a delay in the publication of the Company’s annual results for the year ended 31 March 2025 (the “**2025 Annual Results**”) as additional time is required to, among other things, address requests from the auditors of the Company (the “**Auditors**”) for conducting relevant audit procedures including but not limited to (i) outstanding legal confirmation and opinion in respect of other payables of the Company; and (ii) settlement arrangement for the contingent consideration of the Company.

The Company is working closely with the Auditors to provide the required information and documents to complete the audit procedures as soon as possible. Based on the information currently available to the Company, it is expected that the 2025 Annual Results will be published on Friday, 4 July 2025 and the annual report of the Company for the year ended 31 March 2025 will be published by the end of July 2025.

Pursuant to Rule 13.49(3) of the Listing Rules, if the Company is unable to publish the 2025 Annual Results within the prescribed timeframe, it must announce its results prepared based on the financial results which have yet to be agreed upon with the auditors (so far as such information is available). The Board, after due and careful consideration, is of the view that it would not be appropriate for the Company to publish the unaudited management accounts of the Group for the year ended 31 March 2025 at this stage as they may not accurately reflect the financial performance and/or position of the Group and the publication of the unaudited management accounts could cause confusion and may be misleading to the Shareholders and potential investors of the Company.

POSTPONEMENT OF BOARD MEETING

Due to the aforesaid delay in the publication of the 2025 Annual Results, the meeting of the Board (the “**Board Meeting**”) for the purpose of, among other matters, considering and approving the 2025 Annual Results will be postponed. The Board Meeting is scheduled to be held on Friday, 4 July 2025 for the purpose of considering and approving, amongst the others, the 2025 Annual Results.

SUSPENSION OF TRADING OF SHARES

Pursuant to Rule 13.50 of the Listing Rules, if the issuer fails to publish periodic financial information in accordance with the Listing Rules, the Stock Exchange will normally request suspension of trading in the issuer’s securities and the suspension will normally continue until the issuer publishes an announcement containing the requisite financial information. As the Company is unable to publish the 2025 Annual Results on or before 30 June 2025, trading in the shares of the Company on the Stock Exchange is expected to be suspended with effect from 9:00 a.m. on Wednesday, 2 July 2025, pending the publication of the 2025 Annual Results which is expected to be on Friday, 4 July 2025.

The Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
China Health Group Limited
Chung Ho
Chief Executive Officer and Executive Director

Hong Kong, 30 June 2025

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Zhang Fan (chairman), Mr. Chung Ho and Mr. Xing Yong; two non-executive Directors, namely, Mr. Huang Lianhai and Mr. Wang Jingming; and four independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua, Mr. Lai Liangquan and Ms. Yang Huimin.